Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

NIEDRACH WILLIAM L. MD; TONETTI, FREDERICK W. MD; KATZBERG, RICHARD W. MD; MORRIS, THOMAS W. PHD; VENTURA, JANINE A. BS; TOTTERMAN, SAARA MD; COS, LOUIS R. MD
Investigative Radiology: September 1988
Original Investigations: PDF Only
Buy

Ferrioxamine methanesulfonate (S-FDF) is a new magnetic resonance (MR) contrast agent developed to improve magnetic resonance imaging of the abdomen and pelvis. This stable complex of deferoxamine methanesulfonate and iron is excreted in the urine by glomerular filtration modified by active renal tubular resorption. This study examines the acute systemic and renal hemodynamic responses to this agent after intravenous administration either as an infusion of 25 mg/kg over 5 minutes or as a rapid bolus at a dose of 50 mg/kg. In eight anesthetized dogs, renal plasma flow (RPF) was measured with an electromagnetic flow-meter, and GFR was determined by the renal extraction of technetium-99m-DTPA. Mean arterial pressure (MAP), pulse rate, and a lead IIECG were assessed. At a dose of 25 mg/kg over 5 minutes, MAP decreased significantly (control 146.0 ± 6.5 mm Hg vs. 107 ± 18 mm Hg at 2 minutes; P<.05). In two of the eight animals, the MAP dropped below 60 mm Hg. Significant decreases in GFR and RPF also were noted. AH four of the animals receiving the rapid injection of S-FDF experienced profound hypotension (MAP < 50 mm Hg). The drop in heart rate from 152 ± 11.6 bpm to 121 ± 4.9 bpm was associated with a marked depression of the ST wave in the lead II ECG. Further animal studies are needed to assess the mechanism of toxicity and a potential synergism of action with pentobarbital anesthesia.

© Lippincott-Raven Publishers.